Literature DB >> 30095786

Prevalence of Maternal Hepatitis C Virus Infection in Ohio.

Robert M Rossi1, Carri R Warshak.   

Abstract

OBJECTIVE: To quantify the rising prevalence of maternal hepatitis C virus (HCV) infection in Ohio during the peak of the opioid epidemic and to identify maternal characteristics and obstetric outcomes associated with maternal HCV infection.
METHODS: We conducted a population-based retrospective cohort study of all live births in Ohio (2006-2015). Frequency of maternal HCV infection as reported on birth certificates was compared across each year of the study period. Maternal, obstetric, and neonatal characteristics were compared between women with HCV infection in pregnancy with those without HCV infection. Multivariate logistic regression estimated the relative association between HCV infection and various maternal characteristics and obstetric outcomes.
RESULTS: During the 10-year study period, there were 7,069 reported cases of maternal HCV infection at the time of delivery among 1,463,506 (0.5%) live births in Ohio. The rate of maternal HCV infection increased 631% between 2006 and 2015, from 1.6 to 11.7 cases per 1,000 live births (relative risk [RR] 7.6, CI 6.6-8.7, P<.001). After adjusting for various confounders, demographic characteristics associated with HCV infection included cigarette smoking (adjusted RR 8.6, CI 8.0-9.1), Medicaid insurance (adjusted RR 3.6, CI 3.3-3.8), and white, non-Hispanic race (adjusted RR 3.2, 95% CI 2.9-3.5). Coinfection during pregnancy with hepatitis B, gonorrhea, chlamydia, syphilis, and herpes simplex virus infection was also associated with maternal HCV infection. Obstetric and neonatal outcomes associated with maternal HCV infection included cesarean delivery, fetal intolerance of labor, preterm birth, maternal intensive care unit admission, blood transfusion, small for gestational age (less than the 10th percentile), neonatal intensive care unit admission, need for assisted neonatal ventilation, and infant death.
CONCLUSION: Maternal HCV infection has increased more than sevenfold over the past decade in Ohio. Our findings highlight a dramatic rise in maternal HCV infection that parallels the opioid epidemic within Ohio and in neighboring Appalachian states.

Entities:  

Mesh:

Year:  2018        PMID: 30095786     DOI: 10.1097/AOG.0000000000002807

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  6 in total

1.  Rural-Urban Residence and Maternal Hepatitis C Infection, U.S.: 2010-2018.

Authors:  Katherine A Ahrens; Lauren M Rossen; Amanda R Burgess; Kristin K Palmsten; Erika C Ziller
Journal:  Am J Prev Med       Date:  2021-02-25       Impact factor: 6.604

2.  Infective Endocarditis as a Complication of Intravenous Drug Use in Pregnancy: A Retrospective Case Series and Literature Review.

Authors:  Adebayo Adesomo; Veronica Gonzalez-Brown; Kara M Rood
Journal:  AJP Rep       Date:  2020-09-23

3.  Testing for Hepatitis C in Pregnancy: the Time has Come for Routine Rather than Risk-based.

Authors:  Tatyana Kushner; Catherine A Chappell; Arthur Y Kim
Journal:  Curr Hepatol Rep       Date:  2019-05-09

4.  HIV Status and Other Risk Factors for Prevalent and Incident Sexually Transmitted Infection during Pregnancy (2000-2014).

Authors:  Jodie Dionne-Odom; Michelle J Khan; Victoria C Jauk; Jeff Szychowski; Dustin M Long; Suzanne Wallace; Cherry Neely; Karen Fry; Jeanne Marrazzo; Marilyn Crain; Alan T N Tita
Journal:  Infect Dis Obstet Gynecol       Date:  2019-04-01

5.  Hepatitis C Screening in an Underserved U.S. Cohort of Reproductive Age Women.

Authors:  Nicole J Kim; Daniel Holguin; Dylan Bush; Mandana Khalili
Journal:  Hepatol Commun       Date:  2019-07-11

6.  Hepatitis C Seroprevalence Among Consecutive Labor and Delivery Admissions in Two New York City Hospitals.

Authors:  Tatyana Kushner; Claire Park; Dana Masand; Brian Wagner; Marie Grace; Emma Rosenbluth; Clara Rodriquez-Rivas; Hernis de la Cruz; Jessica Overbey; Rhoda Sperling
Journal:  Open Forum Infect Dis       Date:  2020-10-23       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.